Truvada: Recommended for pre-exposure prophylaxis (PrEP)
The United States FDA‘s advisory committee has recommended that Truvada should be approved for HIV prophylaxis. Gilead Sciences Inc is the manufacturer of the drug to be used in combination therapy of AIDS. The drug is a RTI (Reverse Transcriptase Inhibitor), although it can not destroy the virus but stops their replication. Truvada consists of Emtricitabine and Tenofovir Disoproxil Fumarate in a ratio of 2:3.
The potential side effects include muscle pain or weakness, numb or cold feeling in your arms and legs and trouble in breathing. The most important fact is that this medicine should not be taken if you are allergic with emtricitabine (Emtriva) or tenofovir (Viread).